GMDA Profile
Gamida Cell Ltd (GMDA) is a clinical-stage biopharmaceutical company that focuses on the development of cell therapies for the treatment of cancer and orphan genetic diseases. The company's lead product candidate, omidubicel, is a potential curative bone marrow transplant for patients with hematologic malignancies. Omidubicel has been granted Breakthrough Therapy Designation from the FDA and is currently under review for approval. Gamida Cell is also developing a pipeline of products for the treatment of cancer, including GDA-201, which is in Phase 1 clinical trials for the treatment of multiple myeloma and non-Hodgkin lymphoma, and GDA-301, which is in preclinical development for the treatment of solid tumors.
|
